Know Labs Croissance future

Future contrôle des critères 0/6

Les bénéfices de Know Labs devraient diminuer de 13.7% par an tandis que son chiffre d'affaires annuel devrait croître de 150.1% par an. Le BPA devrait croître de en baisse de 15.9% par an.

Informations clés

-13.7%

Taux de croissance des bénéfices

-15.9%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.1%
Taux de croissance des recettes	150.1%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	15 Aug 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

NYSEAM:KNW - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
9/30/2026	6	-22	N/A	-20	1
9/30/2025	N/A	-19	N/A	-15	1
9/30/2024	N/A	-17	-13	-13	N/A
6/30/2024	N/A	-16	-11	-11	N/A
3/31/2024	N/A	-21	-11	-11	N/A
12/31/2023	N/A	-20	-11	-11	N/A
9/30/2023	N/A	-20	-10	-10	N/A
6/30/2023	N/A	-23	-12	-12	N/A
3/31/2023	N/A	-17	-12	-12	N/A
12/31/2022	0	-19	-8	-8	N/A
9/30/2022	4	-20	-8	-7	N/A
6/30/2022	4	-22	-6	-5	N/A
3/31/2022	4	-26	-6	-5	N/A
12/31/2021	4	-25	-8	-7	N/A
9/30/2021	N/A	-25	-7	-7	N/A
6/30/2021	N/A	-22	-6	-6	N/A
3/31/2021	N/A	-18	-6	-5	N/A
12/31/2020	0	-16	-5	-5	N/A
9/30/2020	0	-14	-4	-4	N/A
6/30/2020	0	-12	-4	-4	N/A
3/31/2020	1	-12	-4	-4	N/A
12/31/2019	1	-10	-3	-3	N/A
9/30/2019	2	-8	-3	-3	N/A
6/30/2019	2	-5	-2	-2	N/A
3/31/2019	3	-4	-2	-2	N/A
12/31/2018	4	-3	-1	-1	N/A
9/30/2018	4	-3	-1	-1	N/A
6/30/2018	5	-3	N/A	-1	N/A
3/31/2018	5	-2	N/A	-1	N/A
12/31/2017	5	-2	N/A	-1	N/A
9/30/2017	5	-4	N/A	-1	N/A
6/30/2017	5	-4	N/A	-2	N/A
3/31/2017	6	-3	N/A	-2	N/A
12/31/2016	6	-2	N/A	-3	N/A
9/30/2016	6	-2	N/A	-3	N/A
6/30/2016	6	-3	N/A	-2	N/A
3/31/2016	6	-4	N/A	-1	N/A
12/31/2015	6	-1	N/A	0	N/A
9/30/2015	6	-3	N/A	0	N/A
6/30/2015	7	0	N/A	-1	N/A
3/31/2015	7	1	N/A	-1	N/A
12/31/2014	8	-3	N/A	-2	N/A
9/30/2014	8	-1	N/A	-1	N/A
6/30/2014	8	-2	N/A	-2	N/A
3/30/2014	8	-6	N/A	-3	N/A
12/31/2013	8	-7	N/A	-3	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: KNW devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: KNW devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: KNW devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: KNW ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: KNW ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de KNW devrait être élevé dans 3 ans

Know Labs Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Know Labs, Inc Announces Executive Appointments

Know Labs Receives Non Compliance Letter from NYSE American Regarding Sections 1003(a)(ii) and 1003(a)(iii)

High number of new and inexperienced directors

Know Labs, Inc. Announces Board and Committee Changes

Know Labs, Inc. has completed a Composite Units Offering in the amount of $3.445 million.

Know Labs, Inc., Annual General Meeting, Sep 26, 2024

Know Labs, Inc. Publishes Clinical Results in Leading Diabetes Journal

Know Labs, Inc. Announces Further Interim Results from a Clinical Research Study

Know Labs, Inc. Announces the Appointment of Chris Somogyi as President, International

Know Labs, Inc. to Present Clinical Research At the 2024 American Association of Clinical Endocrinology Annual Meeting

Know Labs, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Know Labs, Inc. Announces Interim Results from its Most Recent Clinical Research Study

Know Labs, Inc. Announces Board Appointments

Know Labs, Inc. Expands Board of Directors

Know Labs, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Know Labs, Inc., Annual General Meeting, Sep 22, 2023

Know Labs, Inc. Demonstrates Improved Accuracy of Machine Learning Model for Non-Invasive Glucose Monitor

Know Labs Completes Build of Portable Generation 1 Prototype for Non-Invasive Glucose Monitoring

Know Labs, Inc. Furthers External Validation of Bio-RFID(TM) Technology with Study Published in Sensors Journal

Know Labs, Inc. Study Validates Technical Feasibility of Its Novel Sensor for Non-Invasive Glucose Monitoring

Know Labs, Inc. Announces Changes to Executive Leadership Team

Know Labs, Inc. Announces Management Changes

Know Labs Common Stock Deleted from OTC Equity

Know Labs, Inc. has completed an IPO in the amount of $7.2 million.

Know Labs, Inc., Annual General Meeting, Sep 15, 2022

Know Labs, Inc. Announces Executive Appointments

Know Labs, Inc. Announces Executive Appointments

Know Labs Outlines Preparations for Pre-Submission Meeting with FDA

Know Labs, Inc. announced delayed 10-Q filing

Know Labs, Inc. Receives IRB Approval to Begin Internal Clinical Trial of Non-Invasive Glucose Monitoring Technology Bio-RFID™

Know Labs, Inc. Announces Introduction of New KnowU™ Diagnostic Device

Know Labs Receives New Patent for Its Non-Invasive Diagnostic Technology Platform, Bringing Patents Issued and Pending to Nearly 60

Know Labs Announces Successful Results from Pre-Clinical Study Validating Bio-RFID™ Platform Technology

Know Labs, Inc. announced that it has received $14.279 million in funding

Texas Biomedical Research Institute Issues Preliminary Results for Know Labs, Inc.'s Particle Bulb's Ability to Inactivate the SARS-CoV-2 Virus

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance